Chris Pak
Vorstandsvorsitzender bei Molecular Targeting Technologies, Inc.
Profil
Chris Pak has worked as the President & Chief Executive Officer at Molecular Targeting Technologies, Inc. since 2001.
Aktive Positionen von Chris Pak
| Unternehmen | Position | Beginn |
|---|---|---|
Molecular Targeting Technologies, Inc.
 Molecular Targeting Technologies, Inc. BiotechnologyHealth Technology Molecular Targeting Technologies, Inc. is a clinical stage biotech company that develops targeted radiotherapeutics for rare cancers. The private company is based in West Chester, PA. The company's lead platform technology is owned under an exclusive worldwide license to commercialize Evans Blue (EB) platform patents from NIH. This transformative technology has applications in several cancers overexpressing somatostatin receptor type 2 (SSTR2), like Hürthle cell thyroid carcinoma. The company is committed to building value by acquiring and translating innovative radiotherapeutic and imaging assets to improve human health, reduce healthcare costs, and reward stakeholders. MTTI is also building a research reagents business and manufactures and sells an ever-expanding portfolio of products, primarily based upon fluorescence, to meet the needs of cutting-edge academic researchers. The company was founded in 1993. Chris Pak has been the CEO of the company since 2001. | Vorstandsvorsitzender | 01.12.2001 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Molecular Targeting Technologies, Inc.
Molecular Targeting Technologies, Inc. BiotechnologyHealth Technology Molecular Targeting Technologies, Inc. is a clinical stage biotech company that develops targeted radiotherapeutics for rare cancers. The private company is based in West Chester, PA. The company's lead platform technology is owned under an exclusive worldwide license to commercialize Evans Blue (EB) platform patents from NIH. This transformative technology has applications in several cancers overexpressing somatostatin receptor type 2 (SSTR2), like Hürthle cell thyroid carcinoma. The company is committed to building value by acquiring and translating innovative radiotherapeutic and imaging assets to improve human health, reduce healthcare costs, and reward stakeholders. MTTI is also building a research reagents business and manufactures and sells an ever-expanding portfolio of products, primarily based upon fluorescence, to meet the needs of cutting-edge academic researchers. The company was founded in 1993. Chris Pak has been the CEO of the company since 2001. | Health Technology |
